GRTXD · Galera Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, it expects its existing cash and cash equivalents as of March 31, 2026 will not enable the Company to fund its operating expenses and capital expenditure requirements for more than one year after the date these consolidated financial statements are issued, and therefore management has concluded that substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 13, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jul 13, 2026.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRTXD
this stock
Galera Therapeutics, Inc.
|
$3.05B | — | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Ascentis Independent Advi…
Performance
Raw-price comparisons begin at the captured split on Jul 13, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRTXD | +14.7% | — | — | +21.6% | — |
| SPY | +2.5% | +0.9% | +9.2% | +1.4% | +11.1% |
| vs SPY | +12.2% | — | — | +20.2% | — |